Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Conditions:   Non Small Cell Lung Cancer;   ALK Gene Mutation Interventions:   Drug: Brigatinib 180 MG;   Drug: Carboplatin;   Drug: Pemetrexed Sponsor:   Intergroupe Francophone de Cancerologie Thoracique Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials